Fluocinolone Acetonide Intravitreal Implant Shortage

• • Yutiq intravitreal implant, Ani Pharmaceuticals, 0.18 mg prefilled syringe, 1 count, NDC 68611-0180-01

• • Ani Pharmaceuticals did not provide a reason for the shortage.

• • Iluvien intravitreal implant, Ani Pharmaceuticals, 0.19 mg prefilled syringe, 1 count, NDC 68611-0190-02

Estimated Resupply Dates

• • Ani Pharmaceuticals has Yutiq 0.18 mg intravitreal implant on long term back order and the company cannot estimate a resupply date.

Implications for Patient Care

• • Fluocinolone acetonide intravitreal implant is used for patients with chronic non-infectious uveitis affecting the posterior segment of the eye. [1-3]
  • Iluvien is also used for specific patients with diabetic macular edema. [1]

Alternative Agents & Management

• • Both Yutiq 0.18 mg and Iluvien 0.19 mg deliver fluocinolone acetonide at an initial rate of 0.25 mcg/day for 36 months. [1, 2]
  • Bausch Health has Retisert 0.59 mg available, which delivers fluocinolone acetonide at an initial rate of 0.6 mcg/day in the first month and a steady-state rate of 0.3-0.4 mcg/day for 30 months. [3]
  • Retisert is surgically implanted into the posterior segment of the eye via an incision, while Iluvien and Yutiq are injected into the vitreous cavity. [1-3]

References

• 1. Iluvien [package insert]. Alpharetta, GA: Alimera Sciences, Inc., 202.
  2. Yutiq [package insert]. Alpharetta, GA: Alimera Sciences, Inc. , 2023.
  3. Retisert [package insert]. Bridgewater, NJ: Bausch and Lomb Americas Inc, 2025.